NCT00375427View on ClinicalTrials.gov

Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions

PHASE3CompletedINTERVENTIONAL
Enrollment

430

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

February 28, 2010

Conditions
Breast Cancer With Bone Metastasis
Interventions
DRUG

Zoledronic acid

Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.

Trial Locations (1)

Unknown

Novartis Investigative Site, Forlì

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY